Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults
Christine M. Oshansky(St. Jude Children's Research Hospital), Rubén O. Donis(Centers for Disease Control and Prevention), Corrina Pavetto(Biomedical Advanced Research and Development Authority), Michael O’Hara(Biomedical Advanced Research and Development Authority), Robert Walker(University of Edinburgh), James C. King(Biomedical Advanced Research and Development Authority), Karen Biscardi(Biomedical Advanced Research and Development Authority), Brett Jepson(AstraZeneca (South Korea)), Bai V. Nguyen(National Institutes of Health), Di Lü(Duke Kunshan University), Rick A. Bright(Waterford Institute), Vittoria Cioce(Biomedical Advanced Research and Development Authority), Gary Horwith(Biomedical Advanced Research and Development Authority), Penny Hylton(Biomedical Advanced Research and Development Authority), Chad Colfer(Biomedical Advanced Research and Development Authority), Silvija Tresnjak-Smith(Biomedical Advanced Research and Development Authority), Li‐Mei Chen(Sun Yat-sen University), James Zhou(Biomedical Advanced Research and Development Authority), James J. Little(University of British Columbia), Robert A. Johnson(Biomedical Advanced Research and Development Authority), Bai Yeh(Biomedical Advanced Research and Development Authority), John J. Treanor(University of Maryland, Baltimore)
Cited by 10
Related Papers
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Antigenic and Genetic Characteristics of Swine-Origin 2009 A(H1N1) Influenza Viruses Circulating in Humans
|Science|2009|2.5k
Influenza
|Nature Reviews Disease Primers|2018|1.5k
New World Bats Harbor Diverse Influenza A Viruses
|PLoS Pathogens|2013|1.3k